NICE’s evolving HealthTech approach: what it means for the NHS and industry
The NHS has long been a testing ground for innovation, but scaling new technologies has often been slower and fragmented. Now, NICE is changing HealthTech adoption in the NHS through a more structured and flexible approach. From early use pathways to nationally mandated funding routes, these changes are reshaping how technologies move from development to real-world impact.
The NHS has historically been strong at trialling innovations but slower when it comes to adopting them at scale. Groundbreaking technologies, from AI diagnostics to smart wearables, are developed and piloted in the UK, yet rolling them out consistently across the health system has often been slow and fragmented.
To help address this, the National Institute for Health and Care Excellence (NICE) has introduced an evolving set of programmes and guidance designed to accelerate and systematise the path for HealthTech from development to routine patient use. Here is a practical look at how the system is changing, and where the hurdles remain.
A more flexible lifecycle for evaluation
Historically, NICE assessments for HealthTech were often one-off, producing guidance that struggled to keep pace with rapidly evolving products. The new approach adopts a lifecycle perspective, recognising that technology, evidence, and clinical practice evolve over time. This model comprises distinct types of guidance:
Early use: for promising technologies addressing urgent NHS needs. Products receive conditional recommendations while further evidence is collected in real-world settings. This route formalises the previously piloted Early Value Assessment (EVA) into a core part of the HealthTech lifecycle, providing conditional recommendation for technologies with a clear plan for real-world evidence generation.
Routine use: for technologies with mature evidence. Guidance supports broader adoption, considering clinical and economic value, and is intended to guide implementation across multiple sites. Evidence requirements are applied proportionately to the technology and decision question.
Existing use: for technologies already in the NHS. Guidance is comparative and procurement-oriented, helping health systems make informed choices about which products to continue, replace, or retire. It also aims to reduce unwarranted variation and support commissioning decisions.
Expanded Technology Appraisal via the National HealthTech Access Programme (NHAP): within routine use guidance, a small number of high-impact technologies may follow a pathway similar to medicines via expanded Technology Appraisal guidance, creating a stronger expectation of national adoption and signalling greater system priority. Crucially, technologies approved via the NHAP carry a legal funding mandate similar to medicines. While this removes the primary financial barrier, successful adoption still requires innovators to prove implementation readiness, ensuring the NHS has the staff and infrastructure in place to actually use the tool.
Each guidance type carries different evidence requirements, operational commitments, and implications for adoption, making it essential for innovators to understand where their product fits.
The funding gap: HealthTech vs medicines
One of the most persistent challenges for HealthTech is funding. Positive NICE Technology Appraisals for medicines trigger a legal NHS funding mandate. For most HealthTech, even with NICE guidance, adoption decisions largely sit with local Integrated Care Boards (ICBs) or NHS trusts. A key development from this year is that a small number of technologies evaluated via the NHAP carry a national reimbursement mandate akin to medicines. However, it’s important to note that for the time being, the vast majority of HealthTech will not follow this pathway.
Early NHAP topics include AI tools in histopathology and capsule sponge testing for oesophageal cancer pathways. For innovators, this brings both significant advantages and demanding requirements:
Stronger national signal: greater likelihood of consistent adoption and reimbursement across the NHS.
Implementation readiness required: technologies must be demonstrably deployable at scale, with a clear service model, integration into existing systems, appropriate training, safety monitoring, and operational support.
Even with a positive NHAP outcome, commercial success requires executing evidence generation and demonstrating implementation readiness in parallel.
The hidden hurdles to adoption
Even clinically effective and cost-saving technologies can struggle if they do not fit NHS delivery realities. NICE is increasingly emphasising operational value alongside clinical and economic evidence. Key factors include:
Workforce impact: does the tool save time or introduce new burdens?
Digital integration: can it interoperate with existing NHS systems?
Operational relevance: does it address urgent pressures, such as elective recovery or hospital flow?
These factors are critical in both NICE evaluations and local adoption decisions.
The state-of-play for innovators
For innovators, NICE’s evolving approach provides a clearer pathway, particularly for technologies addressing high-priority NHS challenges. The lifecycle model allows earlier engagement with the system, while the NHAP signals what success can look like for nationally important technologies.
However, the bar remains high. Evidence generation is ongoing, not a one-off milestone. Real-world impact must be demonstrated in complex NHS environments.
Furthermore, a positive NICE recommendation provides credibility and sends a powerful signal but is not a guarantee of adoption. Success depends on operational readiness, stakeholder alignment, and navigating local procurement.
The bigger picture
Taken together, these developments reflect a broader shift in how the NHS handles innovation. NICE is moving from evaluating HealthTech at arm’s length to actively supporting access to promising technologies. While significant challenges remain, particularly around funding, local capacity, and implementation, the trajectory is clear: toward a system better equipped to identify, assess, and deploy innovation at scale.
For patients, this means earlier access to impactful technologies. For innovators, it offers a more transparent and structured, if still demanding, route into the NHS.
If your company is navigating complex market access pathways for a digital health product, Hardian Health can help. Get in touch to discover how our expertise can support your journey from concept to clearance.
